- Conditions
- Human Papillomavirus Vaccines
- Interventions
- Community Pharmacists Vaccinating Against Cancer
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Mesa, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 310
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Human Papillomavirus Infection
- Interventions
- Not listed
- Lead sponsor
- Sanford Health
- Other
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Head and Neck Cancer
- Interventions
- Induction Chemotherapy followed by Response Adapted Chemoradiation
- Radiation
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Oropharynx Cancer
- Interventions
- Adjuvant Radiation Therapy, Docetaxel, Cisplatin
- Radiation · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
- Interventions
- Diagnostic tests for anal cancer screening
- Diagnostic Test
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Charleston, South Carolina • Houston, Texas
- Conditions
- Herpes Simplex Infections, Human Papillomavirus, Epstein-Barr Virus Infections, Varicella-zoster Virus Infection, Cytomegalovirus Infections
- Interventions
- Gene-Eden-VIR/Novirin
- Dietary Supplement
- Lead sponsor
- The Center for the Biology of Chronic Disease
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Valley Cottage, New York
- Conditions
- Cervical Carcinoma, Human Papillomavirus Infection
- Interventions
- Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more
- Conditions
- Cervical Cancer, Human Papillomavirus Infection
- Interventions
- Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation
- Behavioral
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years to 65 Years · Female only
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Oropharyngeal Neoplasms
- Interventions
- Intensity-modulated radiation therapy (IMRT), Cisplatin
- Radiation · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • St Louis, Missouri
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx
- Interventions
- paclitaxel, carboplatin, intensity-modulated radiation therapy, quality-of-life assessment
- Drug · Radiation · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, Base of Tongue Carcinoma, Tonsil Cancer
- Interventions
- Transcervical Oropharyngeal Ultrasound, Oral Rinse Collection, Blood Draw
- Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Interventions
- VGX-3100, Matched Placebo, CELLECTRA™-5PSP
- Biological · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Danbury, Connecticut • Newark, Delaware + 24 more
- Conditions
- Cervical Cancer
- Interventions
- Cemiplimab, ISA101b
- Drug · Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Orange, California
- Conditions
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Interventions
- Utomilumab, ISA101b
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Lung Cancer, Nonsmall Cell, Melanoma (Skin)
- Interventions
- Tumor Profiling
- Diagnostic Test
- Lead sponsor
- Repertoire Immune Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Ann Arbor, Michigan • Nashville, Tennessee
- Conditions
- Adult Solid Tumor
- Interventions
- SQZ-eAPC-HPV, Pembrolizumab
- Biological
- Lead sponsor
- SQZ Biotechnologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Duarte, California • Aurora, Colorado + 5 more
- Conditions
- Neoplasms
- Interventions
- BI 754091
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 7
- States / cities
- Sarasota, Florida • Harvey, Illinois • Detroit, Michigan + 4 more
- Conditions
- Anal Cancer, Nonneoplastic Condition, Precancerous Condition
- Interventions
- Papanicolaou test
- Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation, Gardasil 9
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years to 26 Years · Female only
- Enrollment
- 1,080 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 39
- States / cities
- San Diego, California • Wheat Ridge, Colorado • Coral Gables, Florida + 33 more
- Conditions
- Human Papillomavirus Infection
- Interventions
- APTIMA HPV Assay
- Device
- Lead sponsor
- Gen-Probe, Incorporated
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 2,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Burlington, North Carolina • Maryville, Tennessee
- Conditions
- Infections, Papillomavirus
- Interventions
- Data collection
- Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Years to 25 Years · Female only
- Enrollment
- 1,516 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- HPV-Related Squamous Cell Carcinoma
- Interventions
- HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
- Drug
- Lead sponsor
- Hookipa Biotech GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 19 more
- Conditions
- High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
- Other · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 27 Years to 69 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Seattle, Washington
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma of Larynx, Cancer of Nasopharynx
- Interventions
- BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT)
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts